Developer docs
API playgroundTry for free, no card

Search company profiles

HITS

Full company profile

uuid0003b8a

Namestring
HITS
Legal namestring
HITS Inc.
Websiteurl
hits.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

HITS is a Seoul-headquartered AI biotech company founded in May 2020 that builds physics-informed deep learning platforms to accelerate small-molecule drug discovery. Its core product, HyperLab, is a web-based, browser-accessible platform integrating four modules: Hyper Screening (AI-powered virtual screening with a proprietary 11 trillion compound library and Hyper Screening X scale), Hyper Design (deep generative molecule design based on molecular fragments and scaffolds), Hyper ADME/T (physics-based prediction of solubility, LogP, hERG inhibition, CYP inhibition, metabolic stability, and PAMPA permeability), and Hyper Binding (drug–protein interaction prediction with 3D binding visualization). Underlying technology combines molecular dynamics, computational chemistry, and proprietary deep learning architectures including PIGNet and C3Net, with 18+ peer-reviewed publications and three filed patents as of 2021.

In April 2026 HITS launched a second platform, OmicsHorizon, an Agentic AI platform for life science research focused on bio data analysis automation. The company monetizes through three streams: a subscription SaaS offering (HyperLab with a free trial), Digital CRO / Joint Research professional services for pharma, and technology licensing. Go-to-market combines self-serve global PLG via HyperLab, direct enterprise sales in Korea, and international channel partnerships (eMolecules in the USA, Synple Chem in Switzerland). Customer segments are pharmaceutical and biotech companies (primary), plus academic and research institutions (secondary), including named engagements with MD Anderson Cancer Center, Samsung Medical Center, KAIST, and a domestic non-profit research institute.

HITS is venture-backed (Series A of ₩5.5B led by Korea Investment Partners in late 2021, followed by a 2025 round led by Google DeepMind) and has secured substantial Korean government support, including the AI Star Fellowship (₩11.5B through 2030) and selection for the MSIT AI Specialized Foundation Model Development project (K-Fold). Leadership is anchored by KAIST professor Woo Youn Kim as CEO and co-founder Jaechang Lim as CTO, supported by a team of 11–50 employees.

Short descriptiontext

HITS is a Seoul-based AI biotech founded in 2020 that provides physics-informed deep learning platforms (HyperLab and OmicsHorizon) for small-molecule drug discovery and life science research, serving pharmaceutical, biotech, and academic customers globally via SaaS, CRO services, and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, virtual screening, molecular generative models, ADME/T prediction, computational chemistry
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1HyperLab SaaS Platform
TypeSubscription Recurring
Description

Web-based AI drug discovery platform offered as subscription service. Free trial available for initial customer acquisition with conversion to paid tiers.

hits.ai
2Digital CRO Services
TypeProfessional Services
Description

Joint research and technology CRO services for pharmaceutical and biotech companies requiring custom AI-driven drug discovery projects.

hits.ai
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary AI technologies and platforms to pharmaceutical partners for internal drug discovery programs.

hits.ai
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations, Others
Pricing details1 tier
1Free Trial for HyperLab platform
ModelFreemiumBilling cadenceMonthly
Notes

Free trial available for HyperLab AI drug discovery platform at hyperlab.hits.ai. No pricing tiers publicly disclosed.

hits.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1HyperLab
Description

AI-powered drug discovery web platform offering tools for virtual screening, AI drug design, ADME/T prediction, and molecular property analysis.

hits.ai
+1 more record
Core offering1 text field

HITS builds and sells the HyperLab web-based AI drug discovery platform, which integrates virtual screening, AI-driven molecular design, ADME/T property prediction, and drug-protein binding analysis into a single browser-accessible workflow for pharmaceutical and biotech researchers. The company also offers the OmicsHorizon Agentic AI platform for life science research, plus Digital CRO / Joint Research services and technology licensing of its proprietary physics-informed deep learning models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 11 trillion compound screening capability with Hyper Screening X
+2 more records
Product overview1 text field

HITS offers a dual-product portfolio: HyperLab is a unified web-based AI drug discovery platform combining four integrated modules (Hyper ADME/T for property prediction, Hyper Design for molecular generation, Hyper Binding for interaction analysis, and Hyper Screening for virtual hit discovery) accessible without software installation; OmicsHorizon is a separate Agentic AI platform for life science research focused on bio data analysis automation.

Product and service4 records
1HyperLab
CategoryAI Drug Discovery Platform (SaaS)
Description

Web-based AI drug discovery platform integrating virtual screening (Hyper Screening), AI-driven molecular design (Hyper Design), ADME/T property prediction (Hyper ADME/T), and drug-protein binding analysis (Hyper Binding) into a unified workflow accessible from any PC via web browser without software installation. Target users are pharmaceutical and biotech researchers conducting hit discovery, lead optimization, and ADME/T profiling.

2OmicsHorizon
CategoryAI Life Science Research Platform (SaaS)
Description

Agentic AI platform for life science research providing bio data analysis automation to solve research bottlenecks and improve research productivity. Target users are life science research teams needing automated multi-omics and bio-data workflows.

3Digital CRO / Joint Research Services
CategoryContract Research / Professional Services
Description

Custom AI-driven drug discovery research services for pharmaceutical and biotech partners requiring joint research projects or contract research, leveraging HITS' physics-informed models, generative design capabilities, and ADME/T prediction expertise. Engagement is typically initiated through the website contact form for dedicated enterprise scoping.

4Technology Licensing
CategoryTechnology Licensing
Description

Licensing of proprietary AI technologies and platforms (including physics-informed models and the HyperLab platform) to pharmaceutical partners for use in internal drug discovery programs. Licensing terms include royalty arrangements negotiated per partner.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-01
Description

Global sales partnership signed with Synple Chem (Switzerland) in August 2025 for international distribution of AI drug discovery solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-01
Description

Strategic partnership (MOU) and global sales partnership signed with eMolecules (USA) in May 2025 for international distribution of HyperLab platform. Also signed global sales partnership in August 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

AI Star Fellow Project collaboration with KAIST research team, Samsung Medical Center, and Naver Cloud to develop AI models for disease reasoning, diagnosis, and new drug discovery. Government funding of 11.5 billion KRW through December 2030.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

AI Star Fellow Project consortium partner for developing AI models for disease reasoning, diagnosis, and new drug discovery with KAIST and Naver Cloud.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

AI Star Fellow Project consortium partner providing cloud infrastructure for AI model development alongside KAIST and Samsung Medical Center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Successfully discovered hit compounds using HyperLab platform with MD Anderson Cancer Center in January 2025, demonstrating international enterprise customer success.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insilico Medicine is a leading AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. It is a direct peer to HITS in AI/ML-enabled small molecule discovery, virtual screening, and Digital CRO offerings.

TypeDirect peer
Description

Atomwise operates the AtomNet platform for AI-powered virtual screening and small molecule design, serving pharma and academic partners globally. It competes head-on with HITS's Hyper Screening and Hyper Design modules.

TypeDirect peer
Description

Schrödinger provides physics-based computational chemistry and ML-augmented molecular simulation platforms used widely in pharma drug discovery. Overlaps with HITS's physics-informed AI approach and ADME/T prediction capabilities.

TypeBroad incumbent
Description

Recursion combines high-throughput experimental biology with AI/ML for drug discovery across multiple therapeutic areas. While broader and wet-lab-centric, it is a relevant incumbent in AI-enabled small molecule and phenotypic discovery.

TypeDirect peer
Description

Exscientia is an AI-driven precision medicine company offering end-to-end small molecule design and discovery services to pharma. Directly comparable to HITS's generative AI drug design and CRO model.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and robotics for drug discovery and materials innovation. Directly comparable to HITS on physics-informed AI, virtual screening, and small molecule design.

7Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs (Alphabet) is an AI-first drug discovery company built on DeepMind's AlphaFold. As a well-capitalized AI drug discovery peer, it sets a benchmark for the physics-informed, foundation-model approach HITS is pursuing with K-Fold.

8Iambic Therapeutics
TypeEmerging player
Description

Iambic (formerly Entasis) develops AI-driven small molecule therapeutics with physics-informed models. Comparable to HITS in approach and stage, with overlapping pharma partnership model.

TypeDirect peer
Description

BenevolentAI applies AI to drug discovery and target identification across multiple disease areas. Comparable to HITS's target ID and hit discovery workflows, with a SaaS plus pipeline business model.

TypeEmerging player
Description

Cradle uses generative AI for protein engineering and drug discovery, with a developer platform model. Comparable to HITS's AI design and biologics-adjacent modality extension, though more focused on proteins.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HITS

AI Drug Discovery Softwarehits.ai

HITS is a Seoul-based AI biotech founded in 2020 that provides physics-informed deep learning platforms (HyperLab and OmicsHorizon) for small-molecule drug discovery and life science research, serving pharmaceutical, biotech, and academic customers globally via SaaS, CRO services, and licensing.

What HITS does

HITS is a Seoul-headquartered AI biotech company founded in May 2020 that builds physics-informed deep learning platforms to accelerate small-molecule drug discovery. Its core product, HyperLab, is a web-based, browser-accessible platform integrating four modules: Hyper Screening (AI-powered virtual screening with a proprietary 11 trillion compound library and Hyper Screening X scale), Hyper Design (deep generative molecule design based on molecular fragments and scaffolds), Hyper ADME/T (physics-based prediction of solubility, LogP, hERG inhibition, CYP inhibition, metabolic stability, and PAMPA permeability), and Hyper Binding (drug–protein interaction prediction with 3D binding visualization). Underlying technology combines molecular dynamics, computational chemistry, and proprietary deep learning architectures including PIGNet and C3Net, with 18+ peer-reviewed publications and three filed patents as of 2021.

In April 2026 HITS launched a second platform, OmicsHorizon, an Agentic AI platform for life science research focused on bio data analysis automation. The company monetizes through three streams: a subscription SaaS offering (HyperLab with a free trial), Digital CRO / Joint Research professional services for pharma, and technology licensing. Go-to-market combines self-serve global PLG via HyperLab, direct enterprise sales in Korea, and international channel partnerships (eMolecules in the USA, Synple Chem in Switzerland). Customer segments are pharmaceutical and biotech companies (primary), plus academic and research institutions (secondary), including named engagements with MD Anderson Cancer Center, Samsung Medical Center, KAIST, and a domestic non-profit research institute.

HITS is venture-backed (Series A of ₩5.5B led by Korea Investment Partners in late 2021, followed by a 2025 round led by Google DeepMind) and has secured substantial Korean government support, including the AI Star Fellowship (₩11.5B through 2030) and selection for the MSIT AI Specialized Foundation Model Development project (K-Fold). Leadership is anchored by KAIST professor Woo Youn Kim as CEO and co-founder Jaechang Lim as CTO, supported by a team of 11–50 employees.

HITS firmographics

Firmographics
Name
HITS
Legal name
HITS Inc.
Website
https://hits.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
HITS is a Seoul-based AI biotech founded in 2020 that provides physics-informed deep learning platforms (HyperLab and OmicsHorizon) for small-molecule drug discovery and life science research, serving pharmaceutical, biotech, and academic customers globally via SaaS, CRO services, and licensing.
Ownership category
akta.pro rank

HITS industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Virtual screening
  • Molecular generative models
  • ADME/T prediction
  • Computational chemistry

Where HITS is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

HITS business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations, Others

Revenue model

  1. HyperLab SaaS Platform: Web-based AI drug discovery platform offered as subscription service. Free trial available for initial customer acquisition with conversion to paid tiers.
  2. Digital CRO Services: Joint research and technology CRO services for pharmaceutical and biotech companies requiring custom AI-driven drug discovery projects.
  3. Technology Licensing: Licensing of proprietary AI technologies and platforms to pharmaceutical partners for internal drug discovery programs.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree Trial for HyperLab platform

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

HITS product offering

Product offering

Core offering

HITS builds and sells the HyperLab web-based AI drug discovery platform, which integrates virtual screening, AI-driven molecular design, ADME/T property prediction, and drug-protein binding analysis into a single browser-accessible workflow for pharmaceutical and biotech researchers. The company also offers the OmicsHorizon Agentic AI platform for life science research, plus Digital CRO / Joint Research services and technology licensing of its proprietary physics-informed deep learning models.

Product overview

HITS offers a dual-product portfolio: HyperLab is a unified web-based AI drug discovery platform combining four integrated modules (Hyper ADME/T for property prediction, Hyper Design for molecular generation, Hyper Binding for interaction analysis, and Hyper Screening for virtual hit discovery) accessible without software installation; OmicsHorizon is a separate Agentic AI platform for life science research focused on bio data analysis automation.

Differentiator

Problem solved

Functional benefit

Brands

  • HyperLab: AI-powered drug discovery web platform offering tools for virtual screening, AI drug design, ADME/T prediction, and molecular property analysis.
  • OmicsHorizon

Products and services

  • HyperLab Web-based AI drug discovery platform integrating virtual screening (Hyper Screening), AI-driven molecular design (Hyper Design), ADME/T property prediction (Hyper ADME/T), and drug-protein binding analysis (Hyper Binding) into a unified workflow accessible from any PC via web browser without software installation. Target users are pharmaceutical and biotech researchers conducting hit discovery, lead optimization, and ADME/T profiling.
  • OmicsHorizon Agentic AI platform for life science research providing bio data analysis automation to solve research bottlenecks and improve research productivity. Target users are life science research teams needing automated multi-omics and bio-data workflows.
  • Digital CRO / Joint Research Services Custom AI-driven drug discovery research services for pharmaceutical and biotech partners requiring joint research projects or contract research, leveraging HITS' physics-informed models, generative design capabilities, and ADME/T prediction expertise. Engagement is typically initiated through the website contact form for dedicated enterprise scoping.
  • Technology Licensing Licensing of proprietary AI technologies and platforms (including physics-informed models and the HyperLab platform) to pharmaceutical partners for use in internal drug discovery programs. Licensing terms include royalty arrangements negotiated per partner.

Quantifiable outcome

  • 11 trillion compound screening capability with Hyper Screening X
  • +2 more outcomes

Companies that use HITS

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

HITS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

HITS partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Synple ChemcoreChannel Partner/ Reseller/ Distributor · 1 August 2025Global sales partnership signed with Synple Chem (Switzerland) in August 2025 for international distribution of AI drug discovery solutions.
  • eMoleculescoreChannel Partner/ Reseller/ Distributor · 1 May 2025Strategic partnership (MOU) and global sales partnership signed with eMolecules (USA) in May 2025 for international distribution of HyperLab platform. Also signed global sales partnership in August 2025.
  • KAIST Research TeamcoreStrategic or Co-development Partner · 1 May 2025AI Star Fellow Project collaboration with KAIST research team, Samsung Medical Center, and Naver Cloud to develop AI models for disease reasoning, diagnosis, and new drug discovery. Government funding of 11.5 billion KRW through December 2030.
  • Samsung Medical CentercoreStrategic or Co-development Partner · 1 May 2025AI Star Fellow Project consortium partner for developing AI models for disease reasoning, diagnosis, and new drug discovery with KAIST and Naver Cloud.
  • Naver CloudcoreStrategic or Co-development Partner · 1 May 2025AI Star Fellow Project consortium partner providing cloud infrastructure for AI model development alongside KAIST and Samsung Medical Center.
  • MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 January 2025Successfully discovered hit compounds using HyperLab platform with MD Anderson Cancer Center in January 2025, demonstrating international enterprise customer success.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

HITS competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. It is a direct peer to HITS in AI/ML-enabled small molecule discovery, virtual screening, and Digital CRO offerings.
  • Atomwise: Atomwise operates the AtomNet platform for AI-powered virtual screening and small molecule design, serving pharma and academic partners globally. It competes head-on with HITS's Hyper Screening and Hyper Design modules.
  • Schrödinger: Schrödinger provides physics-based computational chemistry and ML-augmented molecular simulation platforms used widely in pharma drug discovery. Overlaps with HITS's physics-informed AI approach and ADME/T prediction capabilities.
  • Exscientia: Exscientia is an AI-driven precision medicine company offering end-to-end small molecule design and discovery services to pharma. Directly comparable to HITS's generative AI drug design and CRO model.
  • XtalPi: XtalPi combines AI, quantum physics, and robotics for drug discovery and materials innovation. Directly comparable to HITS on physics-informed AI, virtual screening, and small molecule design.
  • BenevolentAI: BenevolentAI applies AI to drug discovery and target identification across multiple disease areas. Comparable to HITS's target ID and hit discovery workflows, with a SaaS plus pipeline business model.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion combines high-throughput experimental biology with AI/ML for drug discovery across multiple therapeutic areas. While broader and wet-lab-centric, it is a relevant incumbent in AI-enabled small molecule and phenotypic discovery.
  • Isomorphic Labs: Isomorphic Labs (Alphabet) is an AI-first drug discovery company built on DeepMind's AlphaFold. As a well-capitalized AI drug discovery peer, it sets a benchmark for the physics-informed, foundation-model approach HITS is pursuing with K-Fold.

Emerging players

  • Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven small molecule therapeutics with physics-informed models. Comparable to HITS in approach and stage, with overlapping pharma partnership model.
  • Cradle Bio: Cradle uses generative AI for protein engineering and drug discovery, with a developer platform model. Comparable to HITS's AI design and biologics-adjacent modality extension, though more focused on proteins.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

HITS social profiles

Digital presence

HITS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HITS leadership team

Management profile

Number of profiles

Profiles3 records

HITS funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HITS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HITS

What does HITS do?

HITS builds and sells the HyperLab web-based AI drug discovery platform, which integrates virtual screening, AI-driven molecular design, ADME/T property prediction, and drug-protein binding analysis into a single browser-accessible workflow for pharmaceutical and biotech researchers. The company also offers the OmicsHorizon Agentic AI platform for life science research, plus Digital CRO / Joint Research services and technology licensing of its proprietary physics-informed deep learning models.

Is HITS a public or private company?

HITS is a private company. It is classified as venture growth investor backed and is currently operating.

When was HITS founded?

HITS was founded in 2020. It employs 51 to 100 people.

Where is HITS based?

HITS is headquartered in Seoul, South Korea, in the Asia region.

How does HITS make money?

Three revenue lines are on record. HyperLab SaaS Platform is the primary driver. The others are digital CRO Services and technology Licensing.

Who are HITS's main competitors?

Direct peers on record are Insilico Medicine, Atomwise, Schrödinger, Exscientia, XtalPi and BenevolentAI. Broad incumbents are Recursion Pharmaceuticals and Isomorphic Labs. Emerging players are Iambic Therapeutics and Cradle Bio.

Does HITS have an API?

No public API is recorded for HITS.

What industry is HITS in?

HITS's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venturesquare"기술만 좋아선 안 된다"…딥테크 6개사가 투자자 앞에서 꺼낸 '시장 해법'Six deep tech companies presented market solutions at the 2026 Laplace x ETRI Deep Tech Investment Forum in Seoul. The companies covered advanced materials, vision AI, hydrogen energy, sports AI, AI semiconductors, and AI bio, with investors focusing on commercialization and market entry. The forum aims to connect source technologies with commercialization and expand investment and cooperation.스타트업엔(StartupN)Korea Investment Accelerator·Korea Investment Partners, hosting a global AI hackathon in Seoul with Anthropic·Refleet.Korea Investment Accelerator and Korea Investment Partners hosted a global AI hackathon in Seoul with Anthropic and Replit, where 38 teams and 90 participants built products in two hours. The winner was Hits with an AI drug development tool, and the event was part of the 'Push to Prod' series.BioWorldHits’ Hyperlab launches as ‘virtual AI lab’ for new drug discoveryHits Inc. has launched Hyperlab, a virtual AI lab designed to support new drug discovery processes, with the initiative led by CEO and cofounder Kim Woo-youn. According to Kim, the approach represents a shift from traditional laboratory work to computer and AI-driven virtual drug discovery, which Kim described as the 'age of digital alchemy.' The announcement marks Hits Inc.'s entry into AI-enabled pharmaceutical research technology.동아사이언스₩11.5 Billion Invested to Develop Korean AI Model for Disease Diagnosis and Drug DiscoveryA KAIST research team launched the 'AI Star Fellow Project' in collaboration with Samsung Medical Center, Naver Cloud, and HITS to develop AI models for disease reasoning, diagnosis, and new drug discovery, backed by 11.5 billion KRW in government funding through December 2030. The project aims to build a high-performance reasoning model integrating medical knowledge systems, a convergent reasoning platform, and secure AI technologies for biomarker discovery. The consortium plans to commercialize clinical diagnostic AI, AI-based molecular target exploration for drug development, and an expandable AI reasoning platform through these industry and medical partners.NaverAI 신약개발 플랫폼 '히츠', 유망기업으로 VC 돈 몰린다Hits, an AI drug development platform company, has successfully completed a Series A funding round totaling 5.5 billion won. The funds will be used to launch a new drug development web platform and advance innovative technologies aimed at streamlining the drug development process. This brings Hits' total investment to 6.5 billion won due to the involvement of both existing and new investors.